Simplex Trading’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Simplex Trading’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-318,200	Closed	-$317K	–	10581
2022 Q4	$317K	Sell	318,200 -61,000	-16%	-$82.2K	﹤0.01%	3671
2022 Q3	$682K	Sell	379,200 -23,500	-6%	-$68.1K	﹤0.01%	3107
2022 Q2	$1.17M	Buy	402,700 +400,400	+17,409%	+$988K	﹤0.01%	2449
2022 Q1	$6K	Sell	2,300 -700	-23%	-$2.2K	﹤0.01%	9367
2021 Q4	$13K	Buy	3,000 +2,700	+900%	+$16.9K	﹤0.01%	8835
2021 Q3	$5K	Hold	300	–	–	﹤0.01%	9312
2021 Q2	$4K	Buy	300 +281	+1,479%	+$5.68K	﹤0.01%	9563
2021 Q1	$41K	Buy	19 +5	+36%	+$136	﹤0.01%	6840
2020 Q4	$43K	Buy	14 +13	+1,300%	+$329	﹤0.01%	6355
2020 Q3	$2K	Buy	+1	New	+$18	﹤0.01%	7481

Simplex Trading's TCRR Position: Q2 2023 in Review

Simplex Trading sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 1,444 shares — an estimated $2K sold.

Simplex Trading first reported a position in TCRR in Q1 2020 and held it in 7 quarters. The position peaked at $40K in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Simplex Trading reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Simplex Trading sold 1,444 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $2K.
Simplex Trading first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 7 quarters.
Simplex Trading's TCR2 Therapeutics Inc. Common Stock position peaked at $40K in Q4 2020.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.